The first two authors, Mattia Cremona and Elisa Calabrò, contributed equally to this article.
Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk
Article first published online: 19 JAN 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 5, pages 1326–1335, 1 March 2010
How to Cite
Cremona, M., Calabrò, E., Randi, G., De Bortoli, M., Mondellini, P., Verri, C., Sozzi, G., Pierotti, M. A., La Vecchia, C., Pastorino, U. and Bongarzone, I. (2010), Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer, 116: 1326–1335. doi: 10.1002/cncr.24868
- Issue published online: 18 FEB 2010
- Article first published online: 19 JAN 2010
- Manuscript Revised: 30 JUN 2009
- Manuscript Accepted: 20 JUN 2009
- Manuscript Received: 11 APR 2009
- lung cancer risk;
- serum amyloid A;
- epidemiologic study
The authors investigated whether early stage lung cancer could be identified by proteomic analyses of plasma.
For the first case-control study, plasma samples from 52 patients with lung cancer and from a group of 51 controls were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. In a second case-control study, a classifier of 4 markers (mass-to-charge ratio, 11,681, 6843, 5607, and 8762) also was tested for validation on plasma from 16 consecutive patients with screen-detected cancer versus 406 healthy individuals. The most relevant marker was identified, and an enzyme-linked immunosorbent assay-based analysis revealed that signal intensity was correlated with concentration.
The classifier had a sensitivity of 94.23% and a specificity of 76.47% in the first study but lost predictive value in the second study. Nevertheless, the 11,681 cluster, which was identified as serum amyloid protein A (SAA), resulted in a multiple logistic regression model that indicated a strong association with lung cancer. When both studies were considered as a together, the odds ratio (OR) for an SAA intensity ≥0.5 was 10.27 (95% confidence interval [CI], 4.64-22.74), whereas an analysis restricted to stage I cancers (TNM classification) revealed an OR of 8.45 (95% CI, 2.76-25.83) for T1 lung cancer and 21.22 (95% CI, 5.62-80.14) for T2 lung cancer.
SAA levels were predictive of an elevated risk of lung cancer, supporting the general view that inflammation is implicated in lung cancer development. Cancer 2010. © 2010 American Cancer Society.